Dawn of light: opportunities and challenges in small cell lung cancer immunotherapy / 中国综合临床

ABSTRACT

Small cell lung cancer accounts for about 15% of all lung cancers, and is a highly invasive neuroendocrine tumor. smoking is a major risk factor. SCLC grows rapidly, has a high metastasis rate and has a poor prognosis. For more than 30 years, the treatment of SCLC has progressed slowly, until the emergence of immunodrugs in recent years, which have achieved certain efficacy in a wide range of patients.